Radcliffe Capital Management’s DexCom DXCM Stock Holding History

Radcliffe Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,000	Closed	-$863K	–	407
2025 Q4	$863K	Buy	+13,000	New	+$840K	0.05%	198

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Radcliffe Capital Management's DXCM Position: Q1 2026 in Review

Radcliffe Capital Management sold out of DexCom (DXCM) in Q1 2026, closing a stake of 13,000 shares — an estimated $863K sold.

Radcliffe Capital Management first reported a position in DXCM in Q4 2025 and held it in 1 quarter. The position peaked at $863K in Q4 2025. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Radcliffe Capital Management reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
Radcliffe Capital Management sold 13,000 DexCom shares in Q1 2026, an estimated $863K.
Radcliffe Capital Management first reported a position in DexCom in Q4 2025 and held it in 1 quarter.
Radcliffe Capital Management's DexCom position peaked at $863K in Q4 2025.
957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Radcliffe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.